AR102915A1 - Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable - Google Patents

Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable

Info

Publication number
AR102915A1
AR102915A1 ARP150103970A ARP150103970A AR102915A1 AR 102915 A1 AR102915 A1 AR 102915A1 AR P150103970 A ARP150103970 A AR P150103970A AR P150103970 A ARP150103970 A AR P150103970A AR 102915 A1 AR102915 A1 AR 102915A1
Authority
AR
Argentina
Prior art keywords
compound
formula
crystals
stable
diazabiciclooctan
Prior art date
Application number
ARP150103970A
Other languages
English (en)
Inventor
Fushihara Kenichi
Ichiki Masato
Furuyama Shusuke
Yokoyama Takuya
Ogawa Takaya
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR102915A1 publication Critical patent/AR102915A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los objetos de la presente solicitud consisten en proporcionar un proceso para producir cristales con facilidad en escala industrial y una composición liofilizada estable de compuesto de fórmula (1). Se halló que sometiendo una solución acuosa que contiene el compuesto de fórmula (1) y una sal inorgánica tal como cloruro de sodio a liofilización da como resultado una composición liofilizada con buena estabilidad de almacenamiento, en donde el compuesto de fórmula (1) es cristalino y también que los cristales del compuesto de fórmula (1) se pueden obtener de dicha solución acuosa sin liofilización. Reivindicación 1: Un proceso para producir cristales de un compuesto representado por la fórmula (1), caracterizado porque comprende la cristalización del compuesto en una solución acuosa que contiene el compuesto y una sal inorgánica.
ARP150103970A 2014-12-05 2015-12-04 Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable AR102915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014246425 2014-12-05

Publications (1)

Publication Number Publication Date
AR102915A1 true AR102915A1 (es) 2017-04-05

Family

ID=56091802

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103970A AR102915A1 (es) 2014-12-05 2015-12-04 Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable

Country Status (18)

Country Link
US (2) US10294224B2 (es)
EP (1) EP3228620B1 (es)
JP (1) JP6779787B2 (es)
KR (1) KR102555657B1 (es)
CN (1) CN107001366B (es)
AR (1) AR102915A1 (es)
AU (1) AU2015355970B2 (es)
BR (1) BR112017010445B8 (es)
CA (1) CA2969192C (es)
ES (1) ES2821826T3 (es)
IL (1) IL252691B (es)
MX (1) MX2017007191A (es)
MY (1) MY190283A (es)
RU (1) RU2732129C2 (es)
SG (1) SG11201704576SA (es)
TW (1) TWI691499B (es)
WO (1) WO2016088863A1 (es)
ZA (1) ZA201704063B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2857401T3 (pl) 2012-05-30 2020-02-28 Meiji Seika Pharma Co., Ltd. NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA
HUE051925T2 (hu) 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
WO2019064065A1 (en) * 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CN111448195A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的晶型及其生产方法
EP3687993A1 (en) * 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
JP6375463B1 (ja) * 2018-02-28 2018-08-15 日本曹達株式会社 ビス(フルオロスルホニル)アミドアルカリ金属塩粉末の製造方法
CN110314163A (zh) * 2018-03-30 2019-10-11 杭州森泽医药科技有限公司 一种拉氧头孢钠药物组合物及应用
JP2022094481A (ja) * 2020-12-15 2022-06-27 大阪瓦斯株式会社 ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
GB1589317A (en) * 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759A (ja) 1983-07-15 1985-01-31 Nippon Soda Co Ltd ホルムアミドオキシム誘導体その製造方法及び農園芸用殺菌剤
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
PL157979B1 (pl) 1989-02-14 1992-07-31 Sprezyna z dwoma stanami równowagi trwalej PL PL
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) * 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
KR100314558B1 (ko) * 1994-05-02 2002-02-28 시오노 호히코 피롤리딜티오카르바페넴유도체의결정과,상기결정을함유한동결건조제제및그제조방법
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CA2822758C (en) 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivative and process for preparing the same
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
BR112013032415B1 (pt) 2011-06-17 2021-07-27 Pfizer Anti-Infectives Ab Processos para preparar compostos e compostos
AU2012303691B2 (en) 2011-08-27 2014-06-19 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
AU2012303693B2 (en) 2011-08-30 2014-07-03 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
PL2857401T3 (pl) 2012-05-30 2020-02-28 Meiji Seika Pharma Co., Ltd. NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA
JP6453222B2 (ja) 2013-09-24 2019-01-16 Meiji Seikaファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
HUE051925T2 (hu) * 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable

Also Published As

Publication number Publication date
RU2017123112A3 (es) 2019-06-25
ZA201704063B (en) 2021-10-27
TWI691499B (zh) 2020-04-21
WO2016088863A1 (ja) 2016-06-09
NZ732214A (en) 2021-10-29
EP3228620B1 (en) 2020-09-02
IL252691B (en) 2020-08-31
CN107001366A (zh) 2017-08-01
BR112017010445B1 (pt) 2024-01-30
US10294224B2 (en) 2019-05-21
ES2821826T3 (es) 2021-04-27
IL252691A0 (en) 2017-08-31
RU2732129C2 (ru) 2020-09-11
EP3228620A1 (en) 2017-10-11
AU2015355970B2 (en) 2020-05-21
CN107001366B (zh) 2020-08-28
BR112017010445A2 (pt) 2017-12-26
US11117895B2 (en) 2021-09-14
RU2017123112A (ru) 2019-01-09
JP6779787B2 (ja) 2020-11-04
SG11201704576SA (en) 2017-07-28
MY190283A (en) 2022-04-12
EP3228620A4 (en) 2018-05-02
TW201629062A (zh) 2016-08-16
BR112017010445B8 (pt) 2024-02-27
US20170327499A1 (en) 2017-11-16
JPWO2016088863A1 (ja) 2017-09-14
CA2969192A1 (en) 2016-06-09
MX2017007191A (es) 2017-08-28
CA2969192C (en) 2023-02-28
US20190202831A1 (en) 2019-07-04
KR20170094272A (ko) 2017-08-17
AU2015355970A1 (en) 2017-06-15
KR102555657B1 (ko) 2023-07-18

Similar Documents

Publication Publication Date Title
AR102915A1 (es) Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112018075284A2 (pt) derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
MX2016002368A (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
MY178407A (en) Process for the production of solid cooling agents
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
AR095297A1 (es) Método para preparar un compuesto de piripiropeno
AR095727A1 (es) Preparación de intermediarios de pirimidina
MY178371A (en) Pharmaceutical preparation
MX2016011023A (es) Formulas cristalinas de grapiprant.
PE20170212A1 (es) Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion
PH12016500913A1 (en) Soap bar
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CU20160157A7 (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112015031572A2 (pt) novo processo para a manutenção de uma razão de isômeros de compostos carotenoides
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
BR112017002204A2 (pt) processo melhorado para o tratamento de biomassa na produção de materiais úteis para biocombustíveis
BR112016024977A2 (pt) processo para a preparação de polimorfos de imidacloprida
BR112016007589A2 (pt) n-hetaril(tio)carbonil-2-(benzocicloalquen-1-il)ciclaminas e seu uso como fungicidas
CY1116535T1 (el) Μεθοδος συνθεσης παραγωγων της 7,8-διμεθοξυ-1,3-διυδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη στην συνθεση της ιβαμπραδινης
BR112015028677A2 (pt) corantes ácidos, processo para a produção dos mesmos e seus usos

Legal Events

Date Code Title Description
FC Refusal